{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:02:12Z","timestamp":1791414132356,"version":"4.3.3"},"reference-count":37,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1016\/j.ijantimicag.2010.01.026","type":"journal-article","created":{"date-parts":[[2010,3,9]],"date-time":"2010-03-09T10:09:29Z","timestamp":1268129369000},"page":"537-543","source":"Crossref","is-referenced-by-count":42,"title":["Antimicrobial characterisation of CEM-101 activity against respiratory tract pathogens, including multidrug-resistant pneumococcal serogroup 19A isolates"],"prefix":"10.1016","volume":"35","author":[{"given":"David J.","family":"Farrell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helio S.","family":"Sader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas J.","family":"Biedenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul R.","family":"Rhomberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald N.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2010.01.026_bib1","unstructured":"World Health Organization. Acute respiratory infections (update September 2009). Geneva, Switzerland, WHO. http:\/\/www.who.int\/vaccine_research\/diseases\/ari\/en\/index.html [accessed 10 February 2010]."},{"key":"10.1016\/j.ijantimicag.2010.01.026_bib2","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1053\/srin.2000.18059","article-title":"The epidemiology of respiratory tract infections","volume":"15","author":"File","year":"2000","journal-title":"Semin Respir Infect"},{"issue":"Suppl. 3","key":"10.1016\/j.ijantimicag.2010.01.026_bib3","doi-asserted-by":"crossref","first-page":"S232","DOI":"10.1086\/591409","article-title":"Is activity against \u2018atypical\u2019 pathogens necessary in the treatment protocols for community-acquired pneumonia? Issues with combination therapy","volume":"47","author":"Bartlett","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"Suppl. 2","key":"10.1016\/j.ijantimicag.2010.01.026_bib4","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1086\/511159","article-title":"Infectious Diseases Society of America\/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults","volume":"44","author":"Mandell","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2010.01.026_bib5","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/jac\/45.2.191","article-title":"The Alexander Project 1996\u20131997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections","volume":"45","author":"Felmingham","year":"2000","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl. S1","key":"10.1016\/j.ijantimicag.2010.01.026_bib6","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/jac\/dkf810","article-title":"The PROTEKT surveillance study: antimicrobial susceptibility of Haemophilusinfluenzae and Moraxellacatarrhalis from community-acquired respiratory tract infections","volume":"50","author":"Hoban","year":"2002","journal-title":"J Antimicrob Chemother"},{"issue":"8 Suppl.","key":"10.1016\/j.ijantimicag.2010.01.026_bib7","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1097\/00006454-200308001-00002","article-title":"Worldwide trends in antimicrobial resistance among common respiratory tract pathogens in children","volume":"22","author":"Jacobs","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijantimicag.2010.01.026_bib8","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJM197810052991402","article-title":"Emergence of multiply resistant pneumococci","volume":"299","author":"Jacobs","year":"1978","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2010.01.026_bib9","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1001\/jama.1994.03510470035031","article-title":"Emergence of drug-resistant pneumococcal infections in the United States","volume":"271","author":"Breiman","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2010.01.026_bib10","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1128\/AAC.40.5.1208","article-title":"Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study","volume":"40","author":"Doern","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2010.01.026_bib11","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa022823","article-title":"Decline in invasive pneumococcal disease after the introduction of protein\u2013polysaccharide conjugate vaccine","volume":"348","author":"Whitney","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2010.01.026_bib12","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1128\/JCM.42.2.764-768.2004","article-title":"Molecular epidemiology of multiresistant Streptococcus pneumoniae with both erm(B)- and mef(A)-mediated macrolide resistance","volume":"42","author":"Farrell","year":"2004","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2010.01.026_bib13","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/INF.0b013e31803df9ca","article-title":"Emergence of 19A as virulent and multidrug resistant pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine","volume":"26","author":"Pelton","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijantimicag.2010.01.026_bib14","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/01.inf.0000253059.84602.c3","article-title":"Increased antimicrobial resistance among nonvaccine serotypes of Streptococcus pneumoniae in the pediatric population after the introduction of 7-valent pneumococcal vaccine in the United States","volume":"26","author":"Farrell","year":"2007","journal-title":"Pediatr Infect Dis J"},{"issue":"Suppl. 3","key":"10.1016\/j.ijantimicag.2010.01.026_bib15","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1469-0691.2009.02726.x","article-title":"Impact of pneumococcal conjugate vaccine on infections caused by antibiotic-resistant Streptococcus pneumoniae","volume":"15","author":"Dagan","year":"2009","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2010.01.026_bib16","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.3201\/eid1508.081187","article-title":"Increase in pneumococcus macrolide resistance, United States","volume":"15","author":"Jenkins","year":"2009","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.ijantimicag.2010.01.026_bib17","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1056\/NEJM200012283432603","article-title":"Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States","volume":"343","author":"Whitney","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2010.01.026_bib18","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1086\/505871","article-title":"Macrolide resistance in bacteremic pneumococcal disease: implications for patient management","volume":"43","author":"Daneman","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2010.01.026_bib19","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/jac\/dkg123","article-title":"Drugs of the 21st century: telithromycin (HMR 3647)\u2014the first ketolide","volume":"51","author":"Ackermann","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2010.01.026_bib20","doi-asserted-by":"crossref","unstructured":"Drugs RD. Cethromycin: A-195773, A-195773-0, A-1957730, Abbott-195773, ABT 773. Drugs RD 2007; 8:95\u2013102.","DOI":"10.2165\/00126839-200708020-00004"},{"key":"10.1016\/j.ijantimicag.2010.01.026_bib21","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1093\/jac\/dkn532","article-title":"In vitro activity of the investigational ketolide cethromycin against macrolide- and penicillin-resistant Streptococcus pneumoniae: review of the 1998 to 2006 Canadian Respiratory Organism Susceptibility Study (CROSS)","volume":"63","author":"Wierzbowski","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2010.01.026_bib22","series-title":"48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 25\u201328 October 2008, Washington, DC","article-title":"Antimicrobial characterization of CEM-101 activity against 331 respiratory tract pathogens including multidrug-resistant pneumococcal serogroup 19A (MDR-19A) isolates","author":"Jones","year":"2008"},{"key":"10.1016\/j.ijantimicag.2010.01.026_bib23","series-title":"48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 25\u201328 October 2008, Washington, DC","article-title":"Activity of CEM-101 compared to other agents against macrolide-susceptible and resistant streptococci","author":"McGhee","year":"2008"},{"key":"10.1016\/j.ijantimicag.2010.01.026_bib24","series-title":"48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 25\u201328 October 2008, Washington, DC","article-title":"In vitro activity of CEM 101, a new ketolide antibiotic against Chlamydia trachomatis and Chlamydia pneumoniae","author":"Roblin","year":"2008"},{"key":"10.1016\/j.ijantimicag.2010.01.026_bib25","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1128\/AAC.00203-09","article-title":"Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, towards Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages","volume":"53","author":"Lemaire","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2010.01.026_bib26","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1128\/AAC.00090-09","article-title":"Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101","volume":"53","author":"Waites","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2010.01.026_bib27","unstructured":"Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 8th ed. Document M7-A8. Wayne, PA: CLSI; 2009."},{"key":"10.1016\/j.ijantimicag.2010.01.026_bib28","unstructured":"Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Nineteenth informational supplement. Document M100-S19. Wayne, PA: CLSI; 2009."},{"key":"10.1016\/j.ijantimicag.2010.01.026_bib29","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0732-8893(97)00067-9","article-title":"Anti-Legionella activity of trovafloxacin compared with seven other antimicrobial agents including an intermethod evaluation","volume":"28","author":"Marco","year":"1997","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2010.01.026_bib30","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1097\/INF.0b013e31819e3f7a","article-title":"Emerging macrolide resistance in Mycoplasma pneumoniae in children: detection and characterization of resistant isolates","volume":"28","author":"Li","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijantimicag.2010.01.026_bib31","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S1473-3099(09)70133-1","article-title":"Emergence of community-acquired meticillin-resistant Staphylococcus aureus strain USA300 as a cause of necrotising community-onset pneumonia","volume":"9","author":"Hidron","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2010.01.026_bib32","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1128\/AAC.00971-07","article-title":"National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005\u20132006 U.S. faropenem surveillance study","volume":"51","author":"Critchley","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2010.01.026_bib33","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1086\/324626","article-title":"Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications","volume":"34","author":"Leclercq","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2010.01.026_bib34","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00284-004-4306-7","article-title":"An examination of the differential sensitivity to ketolide antibiotics in ermB strains of Streptococcus pyogenes and Streptococcus pneumoniae","volume":"49","author":"Champney","year":"2004","journal-title":"Curr Microbiol"},{"key":"10.1016\/j.ijantimicag.2010.01.026_bib35","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1128\/AAC.50.2.817-818.2006","article-title":"Streptococcus pyogenes isolates with high-level macrolide resistance and reduced susceptibility to telithromycin associated with 23S rRNA mutations","volume":"50","author":"Farrell","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2010.01.026_bib36","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1590\/S1806-37132008000900008","article-title":"Community-acquired staphylococcal pneumonia","volume":"34","author":"Santos","year":"2008","journal-title":"J Bras Pneumol"},{"key":"10.1016\/j.ijantimicag.2010.01.026_bib37","series-title":"Abstracts of the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), 16\u201319 May 2009, Helsinki, Finland","article-title":"Antimicrobial characterization of CEM-101: activity against staphylococci, beta-haemolytic and viridians group streptococci","author":"Jones","year":"2009"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857910000750?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857910000750?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,26]],"date-time":"2019-05-26T19:45:50Z","timestamp":1558899950000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857910000750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["S0924857910000750"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2010.01.026","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}